A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Active:	Yes
Cancer Type:	Germ Cell Tumor	NCT ID:	NCT04192344
Trial Phases:	Phase I	Protocol IDs:	ABSK021-101 (primary) NCI-2020-05560
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Abbisko Therapeutics Co, Ltd
NCI Full Details:	http://clinicaltrials.gov/show/NCT04192344

Summary

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in
patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral
ABSK021. Preliminary antitumor activity will also be assessed.

Objectives

The study will start with a dose escalation part of single-agent ABSK021 administered in
repeated 28-day cycles in patients with advanced solid for safety and tolerability. The
expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for
further evaluating safety and tolerability among selected tumor types. Preliminary antitumor
activity will also be assessed.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.